Pharmaron Beijing 将来の成長

Future 基準チェック /16

Pharmaron Beijing利益と収益がそれぞれ年間7%と13.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に12.8% 6.6%なると予測されています。

主要情報

7.0%

収益成長率

6.6%

EPS成長率

Life Sciences 収益成長	31.9%
収益成長率	13.5%
将来の株主資本利益率	12.8%
アナリストカバレッジ	Good
最終更新日	25 Nov 2024

今後の成長に関する最新情報

Recent updates

At CN¥29.44, Is It Time To Put Pharmaron Beijing Co., Ltd. (SZSE:300759) On Your Watch List?

Nov 15

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth

Sep 27

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate

Sep 20

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price

May 12

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Mar 04

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Feb 27

業績と収益の成長予測

SZSE:300759 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	15,979	2,187	2,034	3,107	14
12/31/2025	14,088	1,963	1,758	2,800	16
12/31/2024	12,366	1,844	N/A	2,273	15
9/30/2024	11,795	1,884	371	2,495	N/A
6/30/2024	11,502	1,928	258	2,573	N/A
3/31/2024	11,485	1,483	390	2,969	N/A
12/31/2023	11,538	1,601	-112	2,754	N/A
9/30/2023	11,424	1,553	-214	2,777	N/A
6/30/2023	11,272	1,575	-572	2,564	N/A
3/31/2023	10,887	1,474	-806	2,255	N/A
1/1/2023	10,266	1,375	-807	2,143	N/A
9/30/2022	9,545	1,582	-707	2,037	N/A
6/30/2022	8,793	1,682	-300	2,072	N/A
3/31/2022	8,057	1,664	-242	1,977	N/A
12/31/2021	7,444	1,661	-35	2,058	N/A
9/30/2021	6,849	1,423	-152	1,905	N/A
6/30/2021	6,226	1,258	-79	1,876	N/A
3/31/2021	5,664	1,317	125	1,822	N/A
12/31/2020	5,134	1,172	333	1,649	N/A
9/30/2020	4,717	1,008	532	1,565	N/A
6/30/2020	4,314	865	440	1,283	N/A
3/31/2020	3,953	594	370	1,124	N/A
12/31/2019	3,757	547	184	939	N/A
9/30/2019	3,499	437	146	837	N/A
6/30/2019	3,274	378	247	906	N/A
3/31/2019	3,089	346	230	861	N/A
12/31/2018	2,908	333	150	791	N/A
9/30/2018	2,713	300	-721	692	N/A
12/31/2017	2,294	231	N/A	552	N/A
12/31/2016	1,634	177	N/A	236	N/A
12/31/2015	1,128	74	N/A	217	N/A
12/31/2014	790	21	N/A	12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 300759の予測収益成長率 (年間7% ) は貯蓄率 ( 2.8% ) を上回っています。

収益対市場: 300759の収益 ( 7% ) CN市場 ( 26.3% ) よりも低い成長が予測されています。

高成長収益: 300759の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 300759の収益 ( 13.5% ) CN市場 ( 13.9% ) よりも低い成長が予測されています。

高い収益成長: 300759の収益 ( 13.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 300759の自己資本利益率は、3年後には低くなると予測されています ( 12.8 %)。

Pharmaron Beijing 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target increased by 10.0% to CN¥28.22

Price target increased by 9.1% to CN¥25.66

Price target decreased by 12% to CN¥22.71

Consensus EPS estimates fall by 14%

Price target decreased by 7.3% to CN¥29.29

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023

Recent updates

At CN¥29.44, Is It Time To Put Pharmaron Beijing Co., Ltd. (SZSE:300759) On Your Watch List?

Price target increased by 10.0% to CN¥28.22

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 9.1% to CN¥25.66

Investor sentiment deteriorates as stock falls 25%

New minor risk - Share price stability

Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth

Investor sentiment improves as stock rises 17%

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate

Second quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.25 in 2Q 2023)

Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Price target decreased by 12% to CN¥22.71

Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024

Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price

Pharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.

First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.20 in 1Q 2023)

Pharmaron Beijing Co., Ltd. Announces Executive Changes

Consensus EPS estimates fall by 14%

Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Price target decreased by 7.3% to CN¥29.29

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorates as stock falls 16%

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023

Now 24% undervalued after recent price drop

Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

President recently sold CN¥231m worth of stock

Executive VP & Executive Director recently sold CN¥22m worth of stock

Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 2Q 2022)

Price target decreased by 8.9% to CN¥35.78

Price target decreased by 9.2% to CN¥36.68

Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 27, 2023

Price target decreased by 10% to CN¥58.29

President recently sold CN¥13m worth of stock

Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2022

Investor sentiment deteriorates as stock falls 16%

Now 21% undervalued after recent price drop

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.21 in 1Q 2022)

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 10% to CN¥69.70

Consensus EPS estimates fall by 19%

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 10% to CN¥75.56

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2022

Executive VP & Executive Director recently sold CN¥21m worth of stock

President recently sold CN¥31m worth of stock

President recently sold CN¥72m worth of stock

President recently sold CN¥24m worth of stock

President recently sold CN¥41m worth of stock

President recently sold CN¥48m worth of stock

President recently sold CN¥131m worth of stock

Price target decreased to CN¥81.79

Less than half of directors are independent

Price target decreased to CN¥87.07

Price target decreased to CN¥91.49

Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into equity transfer agreement to acquire 21.6874% stake in Pharmaron (Chengdu) Clinical Services Co., Ltd from Mr. Yu Wu and Mr. Li Xianghao for RMB 506.79 million.

Third quarter 2022 earnings released

Price target decreased to CN¥94.38

Investor sentiment improved over the past week